GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
Oncology
-
-
Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
-
Health Canada approves AbbVie’s Elahere for ovarian cancer
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…
-
China’s NMPA conditionally approves Boehringer’s tablets for NSCLC
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
-
Amphastar and Anji make licence agreement for three new peptides
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…
-
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug…
-
Epkinly breaks ground in Phase III FL trial
Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…
-
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy
The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) to treat adults…
-
BeOne Medicines’ BTK degrader gains EMA PRIME designation
Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European…
-
ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture
Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen…
